Ventripoint Diagnostics Ltd. VPT
TSXV · Canada · Health Technology
CAD 0.08500.00 (0.00%)
Market open· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Proposed collaboration would combine UniDoc's connected-care infrastructure with Ventripoint's AI-enabled cardiac imaging platform VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or ...
Commercial initiative aims to make VMS+ easier for hospitals to evaluate and adoptTORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phase of its commercial strategy for VMS+™ 4.0, its FDA-cleared platform that turns standard heart-ultrasound images into three-dimensional cardiac measurements. The Company is expanding subscription-based access, hospital
Collaboration Inspired by Families' Lived Experiences Aims to Reduce Barriers to Advanced Cardiac Imaging and Ensure No Parent Faces Impossible Decisions When Seeking Answers About Their Child's Heart TORONTO, ONTARIO - June 26, 2026 (NEWMEDIAWIRE) -...
TORONTO, ONTARIO - May 4, 2026 (NEWMEDIAWIRE) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT; OTC:VPTDF) will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), t...
TORONTO, ON - April 28, 2026 (NEWMEDIAWIRE) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX-V:VPT, OTC:VPTDF), is proud to announce that its strategic partner, Lishman Global Inc., has formally submitted Ventripoint's VMS+(TM) 4....
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.